You’re not getting chemo the right way.

Recent scientific studies have shown that as many as 4 out of 5 cancer patients undergoing chemotherapy are not receiving the correct chemo dose.

Drugs affect different people in different ways. Do you know someone who can drink a cup of coffee within minutes of going to bed and sleep soundly through the night despite the caffeine? And yet other people are counting sheep all night long after drinking coffee even hours before bed. This same thing happens with chemo drugs too!

Each Patient Has a Unique Palette.

Imagine two people undergoing the same chemotherapy: Patient 1 is a young, athletic, bodybuilder standing 6 ft. tall and weighing 220 lbs. Patient 2 is older, much less active, and a little overweight, but also stands 6 ft. tall and weighs 220 lbs. These two patients will receive exactly the same dose but will, in all likelihood, respond very differently to the drug.

Currently, doctors determine your chemo dose based on your height and weight using a method called “Body Surface Area”, or BSA. This BSA method of dosing doesn’t take into account your individual metabolism, age, health, gender, and many other factors that can affect how your body might respond to the drug(s) your doctor has prescribed for you. Your doctor cannot tell by looking at you what dose will work best and, because everyone is different, you could be given too much or too little drug.

There’s abetter way.

Getting too much drug (overdose) raises your chance of having severe side effects. This can make you so sick that you may have to skip or change treatments.

Getting too little drug (underdose) lowers your chance of beating your cancer. Your cancer is more likely to come back or spread to other parts of your body.

Which is why MyCare Oncology tests were developed to measure the amount of chemo drugs in your body. Your doctor may use one of these tests to help determine if you are getting too much or too little drug. Your dose can be changed so that it is right for you.

Peace of mind comes from knowing that your cancer treatment has been tailored to your own body. Ask your doctor today, if you are being dosed by BSA or if you could receive a personalized dose of chemo based on a blood test? [Not Available in the US]

There’s abetter way.

Getting too much drug (overdose) raises your chance of having severe side effects. This can make you so sick that you may have to skip or change treatments.

Getting too little drug (underdose) lowers your chance of beating your cancer. Your cancer is more likely to come back or spread to other parts of your body.

Which is why MyCare Oncology tests were developed to measure the amount of chemo drugs in your body. Your doctor may use one of these tests to help determine if you are getting too much or too little drug. Your dose can be changed so that it is right for you.

Peace of mind comes from knowing that your cancer treatment has been tailored to your own body. Ask your doctor today, if you are being dosed by BSA or if you could receive a personalized dose of chemo based on a blood test? [Not Available in the US]

Imatinib and other targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors.

MyImatinib enables hematological-oncologists to identify patients who may be underdosed or who need help staying adherent to the medication. Armed with this information physicians may be able to adjust dosage, change medications or help manage side-effects.

5-fluorouracil (5-FU) is the mainstay of modern regimens for the treatment of colorectal, head & neck, rectal and prostate cancers. A wide range of 5-FU clearance has been observed in numerous studies. Patients receiving BSA-based 5-FU can show up to a 30-fold variability in clearance rates. In fact, there is a lack of correlation between BSA and 5-FU clearance. Such variability contributes to undue toxicity and treatment failure.

Paclitaxel is widely used to treat breast, non-small cell lung, ovarian and digestive tract cancers. Despite being a potentially life-saving drug, it is also quite toxic. Many patients suffer seriously debilitating side effects from their treatment with paclitaxel. Also multiple studies have demonstrated high interpatient variability of paclitaxel plasma drug exposure with BSA-based dosing. Patients receiving BSA-based paclitaxel can show greater than a 10-fold variability in clearance rates.

MyPaclitaxel enables oncologists to identify paclitaxel-treated patients who are at high risk of severe toxicity by measuring their systemic drug exposure. Armed with this information, physicians can do dose optimization. Monitoring patients’ drug levels helps control toxicity throughout the course of treatment, preventing premature treatment discontinuation.

Docetaxel is predominantly used to treat breast cancer, but is also an important component in non-small cell lung, digestive tract, prostate and head & neck cancer treatment regimens. Just as with paclitaxel, many patients suffer severe dose-limiting toxicities on docetaxel. The interpatient PK variability of docetaxel is high when it is administered by BSA-based dosing. Patients receiving BSA-based docetaxel can show greater than a 7-fold variability in clearance rates.

MyDocetaxel gives oncologists a tool to control inter-patient variability. Control of drug exposure may result in less toxicity and improved outcomes.

Imatinib and other targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors.

MyImatinib enables hematological-oncologists to identify patients who may be underdosed or who need help staying adherent to the medication. Armed with this information physicians may be able to adjust dosage, change medications or help manage side-effects.

5-fluorouracil (5-FU) is the mainstay of modern regimens for the treatment of colorectal, head & neck, rectal and prostate cancers. A wide range of 5-FU clearance has been observed in numerous studies. Patients receiving BSA-based 5-FU can show up to a 30-fold variability in clearance rates. In fact, there is a lack of correlation between BSA and 5-FU clearance. Such variability contributes to undue toxicity and treatment failure.

Paclitaxel is widely used to treat breast, non-small cell lung, ovarian and digestive tract cancers. Despite being a potentially life-saving drug, it is also quite toxic. Many patients suffer seriously debilitating side effects from their treatment with paclitaxel. Also multiple studies have demonstrated high interpatient variability of paclitaxel plasma drug exposure with BSA-based dosing. Patients receiving BSA-based paclitaxel can show greater than a 10-fold variability in clearance rates.

MyPaclitaxel enables oncologists to identify paclitaxel-treated patients who are at high risk of severe toxicity by measuring their systemic drug exposure. Armed with this information, physicians can do dose optimization. Monitoring patients’ drug levels helps control toxicity throughout the course of treatment, preventing premature treatment discontinuation.

Docetaxel is predominantly used to treat breast cancer, but is also an important component in non-small cell lung, digestive tract, prostate and head & neck cancer treatment regimens. Just as with paclitaxel, many patients suffer severe dose-limiting toxicities on docetaxel. The interpatient PK variability of docetaxel is high when it is administered by BSA-based dosing. Patients receiving BSA-based docetaxel can show greater than a 7-fold variability in clearance rates.

MyDocetaxel gives oncologists a tool to control inter-patient variability. Control of drug exposure may result in less toxicity and improved outcomes.

Imatinib and other targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors.

MyImatinib enables hematological-oncologists to identify patients who may be underdosed or who need help staying adherent to the medication. Armed with this information physicians may be able to adjust dosage, change medications or help manage side-effects.

5-fluorouracil (5-FU) is the mainstay of modern regimens for the treatment of colorectal, head & neck, rectal and prostate cancers. A wide range of 5-FU clearance has been observed in numerous studies. Patients receiving BSA-based 5-FU can show up to a 30-fold variability in clearance rates. In fact, there is a lack of correlation between BSA and 5-FU clearance. Such variability contributes to undue toxicity and treatment failure.

Paclitaxel is widely used to treat breast, non-small cell lung, ovarian and digestive tract cancers. Despite being a potentially life-saving drug, it is also quite toxic. Many patients suffer seriously debilitating side effects from their treatment with paclitaxel. Also multiple studies have demonstrated high interpatient variability of paclitaxel plasma drug exposure with BSA-based dosing. Patients receiving BSA-based paclitaxel can show greater than a 10-fold variability in clearance rates.

MyPaclitaxel enables oncologists to identify paclitaxel-treated patients who are at high risk of severe toxicity by measuring their systemic drug exposure. Armed with this information, physicians can do dose optimization. Monitoring patients’ drug levels helps control toxicity throughout the course of treatment, preventing premature treatment discontinuation.

Docetaxel is predominantly used to treat breast cancer, but is also an important component in non-small cell lung, digestive tract, prostate and head & neck cancer treatment regimens. Just as with paclitaxel, many patients suffer severe dose-limiting toxicities on docetaxel. The interpatient PK variability of docetaxel is high when it is administered by BSA-based dosing. Patients receiving BSA-based docetaxel can show greater than a 7-fold variability in clearance rates.

MyDocetaxel gives oncologists a tool to control inter-patient variability. Control of drug exposure may result in less toxicity and improved outcomes.

Imatinib and other targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors.

MyImatinib enables hematological-oncologists to identify patients who may be underdosed or who need help staying adherent to the medication. Armed with this information physicians may be able to adjust dosage, change medications or help manage side-effects.

5-fluorouracil (5-FU) is the mainstay of modern regimens for the treatment of colorectal, head & neck, rectal and prostate cancers. A wide range of 5-FU clearance has been observed in numerous studies. Patients receiving BSA-based 5-FU can show up to a 30-fold variability in clearance rates. In fact, there is a lack of correlation between BSA and 5-FU clearance. Such variability contributes to undue toxicity and treatment failure.

Paclitaxel is widely used to treat breast, non-small cell lung, ovarian and digestive tract cancers. Despite being a potentially life-saving drug, it is also quite toxic. Many patients suffer seriously debilitating side effects from their treatment with paclitaxel. Also multiple studies have demonstrated high interpatient variability of paclitaxel plasma drug exposure with BSA-based dosing. Patients receiving BSA-based paclitaxel can show greater than a 10-fold variability in clearance rates.

MyPaclitaxel enables oncologists to identify paclitaxel-treated patients who are at high risk of severe toxicity by measuring their systemic drug exposure. Armed with this information, physicians can do dose optimization. Monitoring patients’ drug levels helps control toxicity throughout the course of treatment, preventing premature treatment discontinuation.

Docetaxel is predominantly used to treat breast cancer, but is also an important component in non-small cell lung, digestive tract, prostate and head & neck cancer treatment regimens. Just as with paclitaxel, many patients suffer severe dose-limiting toxicities on docetaxel. The interpatient PK variability of docetaxel is high when it is administered by BSA-based dosing. Patients receiving BSA-based docetaxel can show greater than a 7-fold variability in clearance rates.

MyDocetaxel gives oncologists a tool to control inter-patient variability. Control of drug exposure may result in less toxicity and improved outcomes.